No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
11c-flumazenil |
Flumazenil |
D00697 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
1件: 206 |
2 |
[18f]fpeb |
- |
- |
- |
- |
3件: 6, 8, 206 |
3 |
[18f]fpeb pet imaging |
- |
- |
- |
- |
1件: 206 |
4 |
Acamprosate |
Acamprosate |
D02780, D07058 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
2件: 6, 206 |
5 |
Acetate |
Acetate |
- |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
6 |
Acidum ascorbicum |
Ascorbic acid |
D00018 |
- |
- |
1件: 206 |
7 |
Acidum ascorbicum d6 |
Ascorbic acid |
D00018 |
- |
- |
1件: 206 |
8 |
Af056 |
- |
- |
- |
- |
1件: 206 |
9 |
Afq056 |
- |
- |
- |
- |
3件: 6, 8, 206 |
10 |
Arbaclofen |
Arbaclofen |
D09791 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
2件: 13, 206 |
11 |
Aripiprazole |
Aripiprazole |
D01164 |
4件: DRD2, DRD3, HTR1A, HTR2A |
12件: Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
2件: 6, 206 |
12 |
Azd7325 |
Azd7325 |
- |
- |
- |
1件: 206 |
13 |
Azd7325 (high-dose) |
Azd7325 |
- |
- |
- |
1件: 206 |
14 |
Azd7325 (low-dose) |
Azd7325 |
- |
- |
- |
1件: 206 |
15 |
Bpn14770 |
Bpn14770 |
- |
- |
- |
1件: 206 |
16 |
Cx516 |
Cx516 |
- |
- |
- |
1件: 206 |
17 |
Cx516 (ampalex®) |
Cx516 |
- |
- |
- |
1件: 206 |
18 |
Donepezil |
Donepezil |
D00670, D07869 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
9件: 5, 6, 13, 46, 78, 124, 127, 156, 206 |
19 |
Egcg |
Epigallocatechin gallate |
- |
- |
- |
8件: 6, 13, 17, 28, 85, 113, 206, 299 |
20 |
Egcg fontup |
Epigallocatechin gallate |
- |
- |
- |
1件: 206 |
21 |
Flumazenil |
Flumazenil |
D00697 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
5件: 6, 13, 17, 18, 206 |
22 |
Fluoxetin |
Fluoxetine |
D00326, D00823 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 13, 179, 206 |
23 |
Gaboxadol |
Gaboxadol |
D04282 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
2件: 201, 206 |
24 |
Ganaxolone |
Ganaxolone |
D04300 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
3件: 145, 152, 206 |
25 |
Lovastatin |
Lovastatin |
D00359 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
10件: 6, 34, 46, 79, 156, 160, 195, 206, 263, 310 |
26 |
Lovastatin, then minocycline/lovastatin |
Minocycline |
D00850, D05045 |
- |
- |
1件: 206 |
27 |
Mavoglurant |
Mavoglurant |
- |
- |
- |
1件: 206 |
28 |
Metformin |
Metformin |
D00944, D04966 |
2件: PRKAA1, PRKAA2 |
19件: AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy (HCM), Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease (NAFLD), Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway |
16件: 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285 |
29 |
Methylphenidate |
Methylphenidate |
D01296, D04999 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
7件: 6, 13, 34, 84, 113, 179, 206 |
30 |
Methylphenidate, fluoxetin, risperidone |
Methylphenidate |
D01296, D04999 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
2件: 179, 206 |
31 |
Mg01ci extended-release tablet |
- |
- |
- |
- |
1件: 206 |
32 |
Mglu5 antagonist |
- |
- |
- |
- |
1件: 206 |
33 |
Minocycline |
Minocycline |
D00850, D05045 |
- |
- |
13件: 2, 6, 8, 13, 46, 85, 90, 94, 162, 201, 206, 280, 299 |
34 |
Minocycline hydrochloride |
Minocycline |
D00850, D05045 |
- |
- |
4件: 13, 201, 206, 299 |
35 |
Minocycline, then minocycline/lovastatin |
Minocycline |
D00850, D05045 |
- |
- |
1件: 206 |
36 |
Nnz-2566 |
- |
- |
- |
- |
2件: 156, 206 |
37 |
Npl-2009 |
- |
- |
- |
- |
1件: 206 |
38 |
Ov101 |
- |
- |
- |
- |
2件: 201, 206 |
39 |
Ov101 (gaboxadol) |
Gaboxadol |
D04282 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
1件: 206 |
40 |
Oxytocin |
Oxytocin |
D00089 |
1件: OXTR |
4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway |
4件: 127, 193, 206, 226 |
41 |
Oxytocin 24iu |
Oxytocin |
D00089 |
1件: OXTR |
4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway |
1件: 206 |
42 |
Oxytocin 48iu |
Oxytocin |
D00089 |
1件: OXTR |
4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway |
1件: 206 |
43 |
Riluzole |
Riluzole |
D00775 |
14件: GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway |
7件: 2, 3, 5, 8, 13, 17, 206 |
44 |
Risperidone |
Risperidone |
D00426 |
2件: DRD2, HTR2A |
11件: Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, cAMP signaling pathway |
5件: 8, 156, 179, 187, 206 |
45 |
Ro 491-7523/f18 |
- |
- |
- |
- |
1件: 206 |
46 |
Ro 491-7523/f19 |
- |
- |
- |
- |
1件: 206 |
47 |
Ro4917523 |
- |
- |
- |
- |
1件: 206 |
48 |
Ro4917523 0.5 mg |
- |
- |
- |
- |
1件: 206 |
49 |
Ro4917523 1.5 mg |
- |
- |
- |
- |
1件: 206 |
50 |
Sertraline |
Sertraline |
D00825, D02360 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
2件: 6, 206 |
51 |
Stx107 |
- |
- |
- |
- |
1件: 206 |
52 |
Stx209 |
- |
- |
- |
- |
1件: 206 |
53 |
Sugar pill |
- |
- |
- |
- |
7件: 6, 49, 67, 70, 86, 206, 226 |
54 |
Tocopheryl acetate |
Acetate |
- |
- |
- |
1件: 206 |
55 |
Vitamin c |
Ascorbic acid |
D00018 |
- |
- |
5件: 10, 192, 206, 211, 212 |
56 |
Vitamin c 10mg/kg vitamin e 10 mg/kg |
Vitamin e |
D02331 |
- |
- |
1件: 206 |
57 |
Vitamin e |
Vitamin e |
D02331 |
- |
- |
11件: 2, 6, 13, 20, 46, 90, 96, 97, 206, 299, 317 |
58 |
Zyn002 - cbd transdermal gel |
- |
- |
- |
- |
1件: 206 |